Aussie medical tech scores big win in US market

Cyclopharm's lung imaging technology is breathing new life into the company's bottom line, with its Technegas product surpassing the million-dollar milestone in US sales, according to Tuesday's ASX announcement.

The Sydney-based company has rapidly expanded its American footprint, with Technegas systems now installed in 27 US medical facilities as of 31 March 2025 – a significant jump from just 17 systems three months earlier.

In less than a year since US commercial launch, the technology has propelled the United States to become Cyclopharm's fourth-largest market globally. At this pace, the company expects the US to claim the top position by year's end.

“Crossing the $US1million sales threshold in the US is validation of our commercial strategy,” said Cyclopharm CEO James McBrayer, who has championed the company's push into the world's largest healthcare market.

Each new installation represents not just a one-off sale but an ongoing revenue stream through consumables – creating what the company describes as “sustainable annuity income.”

The technology, which helps medical professionals visualise lung function using radioactive-labeled carbon particles, has gained further traction with another order from the US Department of Veterans Affairs, expanding the company's reach in the federal healthcare system.

Looking ahead, Cyclopharm plans to set up a manufacturing facility in the US within five years, a move aimed at strengthening supply chains and maintaining long-term profit margins in this burgeoning market.

Picture: credit Cyclomedica/LinkedIn